YDES
YD Bio Limited Ordinary Shares
NASDAQ · Healthcare · Biotechnology · TW
$3.54
−3.54%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +30.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +78.6%
- Free cash flow
- -69.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025